Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 7/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29505499 | 1.00 | IRAK4 (0.45) | IRAK4PIK3C3GSK3BAURKAGSK3A | |
| SCHEMBL23110723 | 0.89 | CDK5 (0.44) | IRAK4GSK3BAAK1MAPK14LCLAT1 | |
| SCHEMBL29613007 | 0.86 | TGFBR1 (0.42) | IRAK4PIK3C3GSK3BAAK1MAPK14 | |
| SCHEMBL16698999 | 0.86 | TGFBR1 (0.42) | IRAK4PIK3C3GSK3BAAK1MAPK14 | |
| SCHEMBL16896319 | 0.83 | AURKA (0.48) | IRAK4PIK3C3GSK3BAURKAGSK3A | |
| SCHEMBL20594857 | 0.83 | IRAK4 (0.52) | IRAK4 | |
| SCHEMBL29505238 | 0.83 | AURKA (0.48) | IRAK4PIK3C3GSK3BAURKAGSK3A | |
| SCHEMBL29612661 | 0.83 | IRAK4 (0.52) | IRAK4 | |
| SCHEMBL21998042 | 0.82 | MAPK14 (0.41) | IRAK4GSK3BMAPK14 | |
| SCHEMBL21996939 | 0.82 | MAPK14 (0.41) | IRAK4GSK3BMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361244-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2025-11-27 | — | — | US | disclosed |
| US-12410193-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-09-09 | — | — | US | disclosed |
| US-20240294547-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-09-05 | — | — | US | disclosed |
| US-11981685-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2024-05-14 | — | — | US | disclosed |
| EP-4353324-A2 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | Aurigene Oncology Limited (IN) | 2024-04-17 | — | — | EP | disclosed |
| US-20230331740-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-10-19 | — | — | US | disclosed |
| US-11691987-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-07-04 | — | — | US | disclosed |
| CN-111362966-B | Bicyclic heterocyclic derivatives as IRAK4 inhibitors | 奥列基因发现技术有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20220056046-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2022-02-24 | — | — | US | disclosed |
| US-10995100-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-05-04 | — | — | US | disclosed |
| US-9732095-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-08-15 | — | — | US | disclosed |
| US-20170152263-A1 | Substituted Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-06-01 | — | — | US | disclosed |
| EP-3157521-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2017-04-26 | — | — | EP | disclosed |
| US-20160340366-A1 | BICYCLIC HETEROCYCLYL DERIVATES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2016-11-24 | — | — | US | disclosed |
| EP-3094329-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-11-23 | — | — | EP | disclosed |
| EP-3092226-A1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-11-10 | — | — | US | disclosed |
| WO-2015193846-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015104662-A1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015104688-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691987-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885PIK3C3 173/4885GSK3B 136/4885 |
| US-20240294547-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885PIK3C3 167/4885GSK3B 114/4885 |
| US-11981685-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885PIK3C3 167/4885GSK3B 114/4885 |
| US-20160340366-A1 | BICYCLIC HETEROCYCLYL DERIVATES AS IRAK4 INHIBITORS | IRAK4, IRAK1, IRAK3 | IRAK4 1/4885PIK3C3 261/4885GSK3B 167/4885 |
| US-20220056046-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885PIK3C3 173/4885GSK3B 136/4885 |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885PIK3C3 281/4885GSK3B 87/4885 |
| US-12410193-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885PIK3C3 167/4885GSK3B 114/4885 |
| US-20230331740-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885PIK3C3 167/4885GSK3B 114/4885 |
| US-10995100-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885PIK3C3 173/4885GSK3B 136/4885 |
| US-20250361244-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885PIK3C3 167/4885GSK3B 114/4885 |
| US-20170152263-A1 | Substituted Indazole Compounds as IRAK4 Inhibitors | IRAK4, IRAK3, IRAK2 | IRAK4 1/4885PIK3C3 704/4885GSK3B 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.